<h4>Background</h4>The prevalence of Trigeminal Neuralgia (TN) in patients diagnosed with multiple sclerosis (MS) is insufficiently understood and controversially reported. This study focused on providing a better understanding of the prevalence of TN in MS patients.<h4>Method</h4>We systematically searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar to identify studies published from January 1, 1990, to December 30, 2020. We included studies reporting the TN prevalence among MS patients and exclude case reports/series and editorial studies, review studies, and non-English written articles. We used pooled prevalence estimates to determine the TN prevalence among MS patients.<h4>Results</h4>Pooled overall TN prevalence among 19 studies and 30,348 MS patients was estimated as 3.4% (95% CI: 1.5%-5.9%) with a high level of heterogeneity among studies (I2=98.92%; p<0.001). The pooled prevalence of TN in male and female patients across 9 surveys was 2.4% (95% CI: 0.5%-5.4%) and 3.8% (95% CI: 0.8%-8.7%), respectively. No heterogeneity between the two groups was observed (p = 0.558). A meta-regression was performed to explore the source of the heterogeneity. None of the candidate covariates, including the year of a study publication, the sample size, the average age of patients, and the disease duration, were significant in the model.<h4>Conclusion</h4>Our results showed that TN is a common problem among patients with MS, predominantly male patients. Future studies should target the general prevalence of pain in MS patients.

BACKGROUND Trigeminal neuralgia (TN) is a well-recognized symptom of multiple sclerosis (MS), yet its clinical characteristics related to MS subtype is poorly studied. Our aim was to evaluate whether development and clinical outcome of TN are influenced by MS phenotype. METHODS In this retrospective cohort study, our database from 2007 to 2022 was reviewed to identify patients who had both the diagnosis of MS and TN, whether TN was an initial symptom of MS or developed later in diagnosis. A detailed medical history and treatment outcome was obtained. Pain status was assessed retrospectively using the Barrow Neurological Institute Pain Scale (BNI-PS), with BNI-PS I-III considered as good pain control and BNI-PS IV-V as poor pain control. RESULTS 58 patients had MS-related TN. 44 patients had relapsing remitting multiple sclerosis (RRMS) at the time of TN diagnosis, 11 had secondary progressive multiple sclerosis (SPMS) at the time of TN diagnosis, and type of MS was not clear in 3 patients at the time of TN diagnosis (either RRMS or SPMS). Over a mean follow up of 18.8 (SD=10.9) years, 30 transitioned to SPMS. TN was refractory to medical management in 9 RRMS and 22 SPMS patients (p = 0.001). TN patients with RRMS required lower median number of pain medications compared to SPMS (p = 0.014). Brain MRI was available in 41 of the entire cohort. Of these, 27 patients had demyelinating lesions in the trigeminal sensory pathway and 14 did not. Patients with existing lesions had a higher chance of failure of medical management (74% versus 36%, p = 0.017) and required surgical intervention (55% versus 7%, p = 0.003). DISCUSSION TN was not seen in primary progressive multiple sclerosis (PPMS). In patients who transitioned to SPMS, TN was more likely to be refractory to medical management. TN was more refractory in the presence of demyelinating plaque involving trigeminal sensory pathway.

Secondary trigeminal neuralgia (STN) results from an identifiable underlying pathology, including tumor compression, multiple sclerosis, arteriovenous malformations, hypertension, structural lesions, inflammation, trauma, or familial genetic conditions. This study, through a comprehensive review of the literature in PubMed, Google Scholar, Web of Science, and the Cochrane Library, explores the multifaceted aspects of STN. This study delves into the diverse etiological factors, focusing on the pathophysiological mechanisms that lead to trigeminal nerve dysfunction. The clinical manifestations of STN often overlap with those of primary trigeminal neuralgia, creating diagnostic challenges and necessitating a thorough evaluation that includes detailed history-taking, advanced neuroimaging, and differential diagnosis to pinpoint the secondary cause. The management of STN is complex and tailored to address the underlying etiology. Pharmacological treatments and surgical interventions such as microvascular decompression (MVD), lesion resection, or gamma knife radiosurgery may be needed. Emerging neuromodulation techniques, such as transcranial magnetic stimulation and deep-brain stimulation, have shown promise in refractory cases, particularly for STN associated with multiple sclerosis or structural lesions. This review emphasizes the importance of a multidisciplinary approach to managing STN, integrating neurological, surgical, and rehabilitative strategies to optimize patient outcomes. This finding highlights the need for further research into the role of advanced neuromodulation techniques and novel therapeutic targets to improve the quality of life of patients with STN. By providing a detailed overview of the STN, this study aims to contribute to a better understanding and management of this debilitating condition.

(e.g., trigeminal neuralgia) Autonomic nervous system disorders (e.g., dysautonomia, multiple system atrophy) Epilepsy Movement disorders of the central A neurological disorder is any disorder of the nervous system. Structural, biochemical or electrical abnormalities in the brain, spinal cord, or other nerves can result in a range of symptoms. Examples of symptoms include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain, tauopathies, and altered levels of consciousness. There are many recognized neurologi Brain: Brain dysfunction according to type: Apraxia (patterns or sequences of movements) Agnosia (identifying things or people) Amnesia (memory) Aphasia (language) Dysarthria (speech) Spinal cord disorders Peripheral nervous system disorders (e.g., Peripheral neuropathy) Cranial nerve disorder (e.g., trigeminal neuralgia) Autonomic nervous system disorders (e.g., dysautonomia, multiple system atrophy) Epilepsy Movement disorders of the central and peripheral nervous system such as Parkinson's disease, essential tremor, amyotrophic lateral sclerosis (ALS), and Tourette syndrome Sleep disorders (e.g., narcolepsy) Some speech disorders (e.g., stuttering) Headaches (e.g., migraine, cluster headache, tension headache) Pain (e.g., complex regional pain syndrome, fibromyalgia) Delirium Dementia (e.g., Alzheimer's disease) Coma and impaired consciousness, (e.g., stupor) Stroke Tumors of the nervous system (e.g., cancer) Multiple sclerosis and other demyelinating diseases Brain infections Meningitis Prion diseases (a type of infectious agent) Neurological disorders in non-human animals are treated by veterinarians.

<h4>Introduction</h4>Pain is a frequent and burdensome symptom in multiple sclerosis (MS), yet it remains underrecognized and undertreated.<h4>Objective</h4>This review summarizes current knowledge on the prevalence, mechanisms, clinical phenotypes, and therapeutic strategies of MS-related pain, with an emphasis on implications for clinical management.<h4>Methods</h4>We conducted a narrative review of the literature, integrating epidemiological, clinical, and mechanistic evidence on pain in MS.<h4>Results</h4>Pain is reported by 29% to 86% of people with MS, and up to one-third describe it as their most distressing symptom. Multiple sclerosis-related pain can be classified mechanistically as nociceptive, neuropathic, nociplastic, or mixed. Common clinical syndromes include migraine, tension-type headache, optic neuritis-related pain, trigeminal neuralgia, painful spasticity, and Lhermitte sign. Nociplastic, fibromyalgia-like widespread pain has recently gained attention but remains poorly defined. Evidence for pharmacological interventions - such as anticonvulsants, tricyclic antidepressants, muscle relaxants, corticosteroids for acute optic neuritis, and nabiximols for spasticity - is limited, with few trials addressing specific pain subtypes. Among nonpharmacological strategies, structured exercise shows the most consistent benefits for MS-related pain, whereas evidence for other approaches, including physiotherapy, psychological interventions, and neuromodulation, remains limited. Nevertheless, multimodal strategies addressing co-occurring fatigue, depression, and sleep disturbance appear most effective.<h4>Conclusion</h4>Pain is common and disabling across all MS phenotypes but is often insufficiently addressed in clinical practice. A mechanism-based classification combined with individualized, multimodal treatment offers the most promising framework to improve patient outcomes.

Trigeminal neuralgia causes severe to excruciating pain that often cannot be successfully reduced with current forms of treatment. The International Association for the Study of Pain (IASP) defines trigeminal neuralgia as a sudden, usually unilateral, powerful, short, stabbing, recurrent episode of pain in the distribution of one or more branches of the trigeminal nerve. Trigeminal neuralgia can be caused by vascular compression of the trigeminal nerve or a tumor process. Pressure on the nerve itself causes nerve demyelination, which is the cause of abnormal depolarization, resulting in the development of ectopic impulses. Pain can be provoked by brushing teeth, shaving, eating, cold, heat, etc. After diagnosing trigeminal neuralgia, magnetic resonance imaging should be performed to rule out multiple sclerosis, a tumor process that can secondarily cause trigeminal neuralgia. The drug of choice for treating trigeminal neuralgia is still carbamazepine. If pharmacological treatment fails, invasive surgical microvascular decompression, stereotactic radiation therapy (gamma knife), percutaneous balloon micro compression, percutaneous glycerol rhizolysis, and percutaneous radiofrequency (RF) may be used.

skin innervation of trigeminal nerve divisions Figure 1-8 Trigeminal Nerve Neuralgia. Lastly, there is … innervation of trigeminal nerve divisions, where pain may occur in trigeminal neuralgia Figure 6-4 Trigeminal … Gutrecht SECTION IX MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISORDERS 46 Multiple Sclerosis Mary Anne Muriello